Related Experiment Video
Updated: Jun 8, 2026
04:50
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Clinically relevant advances in rheumatoid arthritis therapy
Ulf Müller-Ladner1, Elena Neumann, Ingo H Tarner
1Department of Internal Medicine and Rheumatology, Justus-Liebig University Giessen, Division of Rheumatology and Clinical Immunology, Kerckhoff Clinic Benekestrasse 2-8, D-61231 Bad Nauheim Germany.
F1000 Medicine Reports
|October 16, 2010
Summary
Novel biologics, including tumor necrosis factor (TNF) inhibitors and tocilizumab, offer new rheumatoid arthritis (RA) treatment options. Clinical trials also explore denosumab and advanced steroid delivery for RA management.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Biologics have shown success in treating rheumatoid arthritis (RA).
- Several novel drugs are emerging for RA treatment, though not universally approved.
- Existing treatments include tumor necrosis factor (TNF) inhibitors and interleukin-6 receptor antagonists.
Purpose of the Study:
- To review novel biologic and small-molecule drugs for rheumatoid arthritis (RA).
- To highlight advancements in RA therapeutic armamentarium.
- To discuss efficacy and potential side effects of new RA treatments.
Main Methods:
- Review of clinical studies and trials.
- Analysis of novel drug classes including TNF inhibitors, IL-6 receptor antagonists, and anti-RANKL antibodies.
- Examination of new steroid delivery systems and small-molecule developments.
Main Results:
- Certolizumab pegol and golimumab are notable TNF inhibitors for RA.
- Golimumab is effective in patients refractory to other TNF blockers and allows monthly administration.
- Tocilizumab represents a new anti-inflammatory pathway for RA, with potential for novel side effects.
- Denosumab shows efficacy in inhibiting osteoclast activation.
- Slow-release 'tempus tablet' for steroids and small-molecule developments are under clinical investigation.
Conclusions:
- The therapeutic landscape for rheumatoid arthritis (RA) is expanding with novel biologics and drug delivery systems.
- New treatments like tocilizumab offer new mechanisms of action but require monitoring for side effects.
- Ongoing clinical trials are evaluating diverse approaches to improve RA management.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...